ERYTECH Pharma S.A. (ERYP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.1000

-0.0700

(-5.98%)

At close: 04:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	1.1700
Open	1.1900
Bid	1.0100 x 2900
Ask	1.1500 x 1200
Day's Range	1.1000 - 1.1900
52 Week Range	1.0000 - 9.5000
Volume	15,541
Avg. Volume	936,001

Market Cap	36.517M
Beta (5Y Monthly)	1.60
PE Ratio (TTM)	N/A
EPS (TTM)	-1.8520
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	17.83

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ERYP

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Erytech Pharma S.A.
Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Rating
Fair Value
Economic Moat
7 months agoMorningstar

All

GlobeNewswire
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 24, 2022. ERYTECH’s shareholders are her
- Pittsburgh Today Live Chat: May 27, 2022
  CBS-Pittsburgh
- Wednesday evening forecast: May 25, 2022
  WHIO
GlobeNewswire
ERYTECH to Present at the H.C. Wainwright Global Investment Conference
ERYTECH to Present at the H.C. Wainwright Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26
GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2